The Supreme Court has issued a stern warning to Patanjali Ayurveda, cautioning against misleading advertisements and false claims that target modern medicines and vaccinations. Responding to a petition filed by the Indian Medical Association (IMA), the court instructed Patanjali to refrain from making deceptive statements and indicated significant penalties for non-compliance.


Justices Ahsanuddin Amanullah and Prashant Kumar Mishra highlighted that the matter should not be reduced to a mere debate between allopathy/modern medicine and Ayurvedic products. Justice Amanullah emphasized the need for an immediate halt to all false and misleading advertisements by Patanjali Ayurved. He warned of potential fines of up to Rs 1 crore for each product featuring a false claim of curing a specific disease.


Moreover, apart from addressing Patanjali’s advertising practices, the Supreme Court urged the Union to propose measures aimed at tackling misleading medical advertisements more broadly. This action followed concerns raised by the IMA regarding Patanjali’s campaigns, which seemed to criticize modern medicine and vaccination efforts.


The Supreme Court’s intervention underscores the gravity of the issue and emphasizes responsible advertising practices in the medical field. This legal development could potentially impact not only Patanjali but also the wider landscape of medical advertising in India, triggering a reconsideration of regulations and standards to ensure accurate and transparent communication within the healthcare sector.